Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction.

 

Blog | January 20, 2016

At the beginning of each year, I always try to determine what the next big cardiovascular technology advances to...

Abbott, Absorb, BVS, FDA review, FDA panel

The Abbott Absorb BVS.

News | Cath Lab | January 20, 2016 | Dave Fornell

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer...

Blog | Cath Lab | November 05, 2015

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on...

Videos | TCT | November 05, 2015

DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies...

Videos | TCT | November 05, 2015

Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015...

News | Stents Bioresorbable | October 30, 2015

October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable...

Videos | Stents Bioresorbable | October 30, 2015

Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for...

News | Stents Drug Eluting | October 27, 2015

October 27, 2015 — Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA...

Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline

There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT)...

Amaranth Medical Bioresorbable Scaffold, Fortitude stent
News | Stents Bioresorbable | October 16, 2015

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials...

ABSORB III trial, TCT 2015, bioresorbable vascular scaffold, BVS

Abbott's Absorb bioresorbable stent. Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable | October 16, 2015

October 16, 2015 — Results from a clinical trial showed that Abbott's Absorb...

SCAI, new bioabsorbable stent technologies, TCT 2015, Absorb, Synergy

Synergy stent image courtesy of Boston Scientific

News | Stents Bioresorbable | October 15, 2015

October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness...

BIOSOLVE-II Trial results, TCT 2015, Biotronik Bioresorbable Magnesium Scaffold
News | Stents Bioresorbable | October 15, 2015

October 15, 2015 — Biotronik has announced results from...

Synergy stent
Technology | October 05, 2015

October 5, 2015 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s Synergy Bioabsorbable...

ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable | September 04, 2015

September 4, 2015 — A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard...

Overlay Init